|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
mood stabilizer
|
|
gptkbp:ATCCode
|
N03AG01
|
|
gptkbp:boilingPoint
|
221 °C
|
|
gptkbp:brand
|
gptkb:Depakene
gptkb:Depakote
gptkb:Epilim
|
|
gptkbp:CASNumber
|
99-66-1
|
|
gptkbp:category
|
gptkb:carboxylic_acid
antimanic agent
fatty acid derivative
|
|
gptkbp:chemicalFormula
|
C8H16O2
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:discoveredBy
|
gptkb:Pierre_Eymard
|
|
gptkbp:discoveredIn
|
1962
|
|
gptkbp:drugInteraction
|
gptkb:phenytoin
gptkb:warfarin
gptkb:aspirin
gptkb:carbamazepine
gptkb:lamotrigine
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
valproic acid
|
|
gptkbp:IUPACName
|
gptkb:2-propylpentanoic_acid
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks voltage-gated sodium channels
increases GABA levels
|
|
gptkbp:meltingPoint
|
121 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
144.21 g/mol
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:riskFactor
|
liver failure
thrombocytopenia
hyperammonemia
neural tube defects
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
tremor
hair loss
pancreatitis
weight gain
hepatotoxicity
teratogenicity
|
|
gptkbp:solubility
|
slightly soluble
|
|
gptkbp:usedFor
|
bipolar disorder
epilepsy
migraine prophylaxis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:FX-322
|
|
gptkbp:bfsLayer
|
5
|